NGL Fine-Chem Limited (BOM:524774)

India · Delayed Price · Currency is INR

2,655.75

+29.40 (1.12%)

At close: Oct 22, 2026

Market Cap	16.41B +78.3%
Revenue (ttm)	5.36B +40.4%
Net Income	572.83M +170.9%
EPS	92.72 +170.9%
Shares Out	6.18M
PE Ratio	28.64
Forward PE	n/a
Dividend	1.75 (0.07%)
Ex-Dividend Date	Aug 18, 2026

Volume	734
Open	2,699.00
Previous Close	2,626.35
Day's Range	2,615.50 - 2,799.00
52-Week Range	1,261.00 - 3,595.00
Beta	0.87
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About NGL Fine-Chem

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxac... [Read more]

Industry Medicinal Chemicals and Botanical Products

Founded 1981

Employees 498

Stock Exchange Bombay Stock Exchange

Ticker Symbol 524774

Full Company Profile

Financial Performance

In fiscal year 2026, NGL Fine-Chem's revenue was 5.01 billion, an increase of 36.03% compared to the previous year's 3.68 billion. Earnings were 481.27 million, an increase of 127.83%.

Financial Statements